Kevin Rosin
Corneal and Contact Management · New York, NYNPI 1184668121
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $44,160 of the $59,051 with a category attached, or 74.8%. Sun Pharmaceutical Industries Inc. accounts for 77.3% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $16,252, more than ten times the $1,017 reported in 2019. Among corneal and contact management clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 443 payments — averaging $133.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$46K
- Oyster Point Pharma, Inc.$7K
- Alcon$1K
- Tarsus Pharmaceuticals, Inc.$1K
- Bausch & Lomb Americas Inc.$860
- Dompe US, Inc.$489
- plus $3K from 16 others
Across 2 payments — averaging $608.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shire North American Group Inc$1K
What the payments were for
- Speaking & faculty fees$44,16075%
- Travel & lodging$4,6618%
- Food & beverage$9,94417%
- Education$2500%
- Gifts$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 165 | $45,637 |
| Oyster Point Pharma, Inc. | 44 | $6,903 |
| Alcon | 37 | $1,251 |
| Tarsus Pharmaceuticals, Inc. | 43 | $1,043 |
| Bausch & Lomb Americas Inc. | 33 | $860 |
| Dompe US, Inc. | 22 | $489 |
| AbbVie(2 entities) | 15 | $473 |
| Coopervision Inc. | 8 | $386 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 17 | $339 |
| Novartis | 13 | $270 |
| Harrow Eye, LLC | 9 | $267 |
| Kala Pharmaceuticals, Inc. | 10 | $243 |
| Thea Pharma Inc. | 3 | $182 |
| Sight Sciences, Inc. | 6 | $176 |
| Quidel Corporation | 3 | $141 |
| Carl Zeiss Meditec, Inc. | 2 | $117 |
| Biotissue Holdings Inc. | 4 | $86 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $62 |
| Johnson & Johnson Vision Care, Inc. | 2 | $52 |
| Eyevance Pharmaceuticals LLC | 2 | $41 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Shire North American Group Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$43,588
- TYRVAYA$6,057
- XDEMVY$523
- MIEBO$413
- Precision 1$258
- VYZULTA$252
- VEVYE$134
- XIIDRA$130
- VUITY$129
- Onefit Contact Lens$126
- RESTASIS$125
- DAILIES$116
- Oxervate$107
- MyDay Contact Lens$102
- VisuMax$100
How this compares
$59,051 in reported general payments places this provider in the 95th percentile of 68 corneal and contact management providers in New York.
See all corneal and contact management providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $678,044 |
| RestasisCyclosporine | 62 | $47,608 |
| XiidraLifitegrast | 43 | $42,441 |
| XdemvyLotilaner | 18 | $33,371 |
| MieboPerfluorohexyloctane/Pf | 41 | $31,699 |
| CequaCyclosporine | 47 | $26,526 |
| LumiganBimatoprost | 18 | $10,925 |
| TyrvayaVarenicline Tartrate | 11 | $7,983 |
| ProlensaBromfenac Sodium | 20 | $6,861 |
| ZyletTobramycin/Lotepred Etab | 13 | $5,966 |
| Tobradex StTobramycin/Dexamethasone | 26 | $5,966 |
| Lotemax SmLoteprednol Etabonate | 20 | $4,984 |
| Loteprednol Etabonate | 14 | $1,848 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 37 | $1,741 |
| Latanoprost | 13 | $120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $489 | $678,04412 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $860 | $74,14184 claims |
| AbbVieRestasis, Lumigan | $473 | $58,53380 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,043 | $33,37118 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $45,637 | $26,52647 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Zylet, Lotemax Sm, Loteprednol Etabonate | $339 | $19,65967 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $6,903 | $7,98311 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $41 | $5,96626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 68 corneal and contact management providers in New York.
Other corneal and contact management in New York
- Kevork NiksarliNew York$27K
- Christina ChernyNew York$5K
- Nadine EisenbergNew York$4K
- Traci GoldsteinNew York$4K
- Ralph GundelNew York$3K
- James SinowayNew York$3K
- Jennifer leNew York$3K
- Cynthia ZaraNew York$2K
- Frederic NevinsNew York$1K
- Melissa Lee KungNew York$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.